Kenneth C Bedi1, Nathaniel W Snyder1, Jeffrey Brandimarto1, Moez Aziz1, Clementina Mesaros1, Andrew J Worth1, Linda L Wang1, Ali Javaheri1, Ian A Blair1, Kenneth B Margulies1, J Eduardo Rame2. 1. From Cardiovascular Institute University of Pennsylvania Perelman School of Medicine, Smilow Translational Research Center, Philadelphia, PA (K.C.B., J.B., A.J., K.B.M., J.E.R.); A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA (N.W.S.); and Center of Cancer Pharmacology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA (M.A., C.M., A.J.W., L.L.W., I.A.B.). 2. From Cardiovascular Institute University of Pennsylvania Perelman School of Medicine, Smilow Translational Research Center, Philadelphia, PA (K.C.B., J.B., A.J., K.B.M., J.E.R.); A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA (N.W.S.); and Center of Cancer Pharmacology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA (M.A., C.M., A.J.W., L.L.W., I.A.B.). Eduardo.rame@uphs.upenn.edu.
Abstract
BACKGROUND: The failing human heart is characterized by metabolic abnormalities, but these defects remains incompletely understood. In animal models of heart failure there is a switch from a predominance of fatty acid utilization to the more oxygen-sparing carbohydrate metabolism. Recent studies have reported decreases in myocardial lipid content, but the inclusion of diabetic and nondiabetic patients obscures the distinction of adaptations to metabolic derangements from adaptations to heart failure per se. METHODS AND RESULTS: We performed both unbiased and targeted myocardial lipid surveys using liquid chromatography-mass spectroscopy in nondiabetic, lean, predominantly nonischemic, advanced heart failure patients at the time of heart transplantation or left ventricular assist device implantation. We identified significantly decreased concentrations of the majority of myocardial lipid intermediates, including long-chain acylcarnitines, the primary subset of energetic lipid substrate for mitochondrial fatty acid oxidation. We report for the first time significantly reduced levels of intermediate and anaplerotic acyl-coenzyme A (CoA) species incorporated into the Krebs cycle, whereas the myocardial concentration of acetyl-CoA was significantly increased in end-stage heart failure. In contrast, we observed an increased abundance of ketogenic β-hydroxybutyryl-CoA, in association with increased myocardial utilization of β-hydroxybutyrate. We observed a significant increase in the expression of the gene encoding succinyl-CoA:3-oxoacid-CoA transferase, the rate-limiting enzyme for myocardial oxidation of β-hydroxybutyrate and acetoacetate. CONCLUSIONS: These findings indicate increased ketone utilization in the severely failing human heart independent of diabetes mellitus, and they support the role of ketone bodies as an alternative fuel and myocardial ketone oxidation as a key metabolic adaptation in the failing human heart.
BACKGROUND: The failing human heart is characterized by metabolic abnormalities, but these defects remains incompletely understood. In animal models of heart failure there is a switch from a predominance of fatty acid utilization to the more oxygen-sparing carbohydrate metabolism. Recent studies have reported decreases in myocardial lipid content, but the inclusion of diabetic and nondiabeticpatients obscures the distinction of adaptations to metabolic derangements from adaptations to heart failure per se. METHODS AND RESULTS: We performed both unbiased and targeted myocardial lipid surveys using liquid chromatography-mass spectroscopy in nondiabetic, lean, predominantly nonischemic, advanced heart failurepatients at the time of heart transplantation or left ventricular assist device implantation. We identified significantly decreased concentrations of the majority of myocardial lipid intermediates, including long-chain acylcarnitines, the primary subset of energetic lipid substrate for mitochondrial fatty acid oxidation. We report for the first time significantly reduced levels of intermediate and anaplerotic acyl-coenzyme A (CoA) species incorporated into the Krebs cycle, whereas the myocardial concentration of acetyl-CoA was significantly increased in end-stage heart failure. In contrast, we observed an increased abundance of ketogenic β-hydroxybutyryl-CoA, in association with increased myocardial utilization of β-hydroxybutyrate. We observed a significant increase in the expression of the gene encoding succinyl-CoA:3-oxoacid-CoA transferase, the rate-limiting enzyme for myocardial oxidation of β-hydroxybutyrate and acetoacetate. CONCLUSIONS: These findings indicate increased ketone utilization in the severely failing human heart independent of diabetes mellitus, and they support the role of ketone bodies as an alternative fuel and myocardial ketone oxidation as a key metabolic adaptation in the failing human heart.
Authors: Tadahiro Shimazu; Matthew D Hirschey; Lan Hua; Kristin E Dittenhafer-Reed; Bjoern Schwer; David B Lombard; Yu Li; Jakob Bunkenborg; Frederick W Alt; John M Denu; Matthew P Jacobson; Eric Verdin Journal: Cell Metab Date: 2010-12-01 Impact factor: 27.287
Authors: Nathaniel W Snyder; Gregory Tombline; Andrew J Worth; Robert C Parry; Jacob A Silvers; Kevin P Gillespie; Sankha S Basu; Jonathan Millen; David S Goldfarb; Ian A Blair Journal: Anal Biochem Date: 2015-01-06 Impact factor: 3.365
Authors: Mitsuru Seki; Jeffery C Powers; Sonomi Maruyama; Maria A Zuriaga; Chia-Ling Wu; Clara Kurishima; Lydia Kim; Jesse Johnson; Anthony Poidomani; Tao Wang; Eric Muñoz; Sudarsan Rajan; Joon Y Park; Kenneth Walsh; Fabio A Recchia Journal: Circ Heart Fail Date: 2018-01 Impact factor: 8.790
Authors: Haobo Li; Margaret H Hastings; James Rhee; Lena E Trager; Jason D Roh; Anthony Rosenzweig Journal: Circ Res Date: 2020-02-13 Impact factor: 17.367
Authors: Dae Yun Seo; Hyo-Bum Kwak; Amy Hyein Kim; Se Hwan Park; Jun Won Heo; Hyoung Kyu Kim; Jeong Rim Ko; Sam Jun Lee; Hyun Seok Bang; Jun Woo Sim; Min Kim; Jin Han Journal: Pflugers Arch Date: 2019-04-23 Impact factor: 3.657
Authors: Yong Seon Choi; Ana Barbosa Marcondes de Mattos; Dan Shao; Tao Li; Miranda Nabben; Maengjo Kim; Wang Wang; Rong Tian; Stephen C Kolwicz Journal: J Mol Cell Cardiol Date: 2016-09-28 Impact factor: 5.000
Authors: Giuseppe Daniele; Juan Xiong; Carolina Solis-Herrera; Aurora Merovci; Roy Eldor; Devjit Tripathy; Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani Journal: Diabetes Care Date: 2016-08-25 Impact factor: 19.112